Arcutis Biotherapeutics (ARQT) Return on Capital Employed (2020 - 2025)
Arcutis Biotherapeutics has reported Return on Capital Employed over the past 6 years, most recently at 0.04% for Q4 2025.
- Quarterly results put Return on Capital Employed at 0.04% for Q4 2025, up 37.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (up 37.0% YoY), and the annual figure for FY2025 was 0.05%, up 44.0%.
- Return on Capital Employed for Q4 2025 was 0.04% at Arcutis Biotherapeutics, up from 0.15% in the prior quarter.
- Over the last five years, Return on Capital Employed for ARQT hit a ceiling of 0.04% in Q4 2025 and a floor of 1.01% in Q2 2023.
- Median Return on Capital Employed over the past 5 years was 0.55% (2021), compared with a mean of 0.58%.
- Biggest five-year swings in Return on Capital Employed: crashed -50bps in 2022 and later skyrocketed 57bps in 2024.
- Arcutis Biotherapeutics' Return on Capital Employed stood at 0.57% in 2021, then dropped by -21bps to 0.68% in 2022, then tumbled by -30bps to 0.89% in 2023, then surged by 54bps to 0.41% in 2024, then surged by 89bps to 0.04% in 2025.
- The last three reported values for Return on Capital Employed were 0.04% (Q4 2025), 0.15% (Q3 2025), and 0.35% (Q2 2025) per Business Quant data.